RxDoctor Payments Data

Hameed Ali, DO

Internal Medicine · Temple, TXNPI 1104974955

Payments from drug & device makers

$773,237in general payments, 2019–2025

Across 1,856 payments — averaging $416.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$268K
  • Paratek Pharmaceuticals, Inc.$198K
  • AstraZeneca$83K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$75K
  • AbbVie$54K
  • Novartis$28K
  • plus $67K from 29 others

What the payments were for

  • Consulting fees$16,8512%
  • Speaking & faculty fees$584,76976%
  • Travel & lodging$133,83917%
  • Food & beverage$37,4965%
  • Education$2820%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$773,237 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$31,706
Medicare patients
102
Services billed
300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban44$26,810
XareltoRivaroxaban31$24,769
JardianceEmpagliflozin12$8,163
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$1,341
Aripiprazole11$968
Atorvastatin Calcium171$896
Albuterol Sulfate HfaAlbuterol Sulfate31$648
Levetiracetam27$598
Gabapentin57$533
Nifedipine ErNifedipine32$483
Amlodipine Besylate124$440
Quetiapine Fumarate36$376
Lisinopril109$374
Losartan Potassium70$346
Memantine Hcl15$333

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12,207$26,81044 claims
Johnson & JohnsonXarelto$268,141$24,76931 claims
Boehringer IngelheimJardiance$453$8,16312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Temple

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →